#### **REMARKS**

The Specification, Abstract and claims have been amended to insert reference to SEQ ID NOS. found in the Sequence Listing. The Specification further has been amended to include the Sequence Listing, as required by the Notice to Comply (copy attached hereto). The Sequence Listing contains no new matter; therefore, its entry is requested.

RESPECTFULLY SUBMITTED,						
NAME AND REG. NUMBER	Jeffrey L. Ihnen, Registration No. 28,957					
SIGNATURE	Jeffy Ithree			DATE	06 MARCH 2001	
Address	ROTHWELL, FIGG, ERNST & MANBECK, p.c.					
	Suite 701-East, 555 13th Street, N.W.					
City	Washington	State	D.C.		Zip Code	20004
Country	U.S.A.	Telephone	202-783-6040		Fax	202-783-6031

Dated: 06 March 2001

Attachments: Sequence Listing

Marked-Up Copies of Amendments

Statement Pursuant to 37 CFR 1.821(f) with diskette

Serial No. 09/462,931, U.S. National Phase of PCT/FI98/00550, filed 24 June 1998 March 5, 2001 Mark-ups, Page 1

#### Amended Specification Page 5: Version with markings to show changes made

#### SUMMARY OF THE INVENTION

This invention relates to an isolated osteocalcin fragment derived from human urine, said fragment being characterized in that at least one of the glutamic acids in the position 17, 21 and 24 of the amino acid sequence

Val (SEO ID NO:2)

is gamma-carboxylated.

Serial No. 09/462,931, U.S. National Phase of PCT/FI98/00550, filed 24 June 1998 March 5, 2001 Mark-ups, Page 2

# Amended Specification Page 7: Version with markings to show changes made

## BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 A shows the nucleic acid (SEQ ID NO:1) and the amino acid (SEQ ID NO:2) sequences of the synthetic human osteocalcin insert (SEQ ID NO:3). Figure 1 B shows plasmid vector pGEX-3X (Pharmacia). The arrow indicates the SmaI-ligation site of the hOC insert;. The pfXa (protease factor Xa) cleavage site is located after the Ile-Glu-Gly-Arg -sequence (residues 1-4 of SEQ ID NO:4).

Serial No. 09/462,931, U.S. National Phase of PCT/F198/00550, filed 24 June 1998 March 5, 2001 Mark-ups, Page 3

## Amended Claims: Version with markings to show changes made

is gamma-carboxylated.

1 (Amended). An isolated osteocalcin fragment derived from human urine, said fragment characterized in that at least one of the glutamic acids in the position 17, 21 and 24 of the amino acid sequence

7 (Amended) The immunoassay according to claim 6 characterized by employing monoclonal antibodies or recombinant antibody fragments specific to epitopes that have been identified on the gamma-carboxylated fragment of osteocalcin, wherein said fragment spans either

- i) from the amino acid in position 7 to the amino acid in position 30, or
- ii) from the amino acid in position 6 to the amino acid in position 30 of the amino acid sequence described in [SEQ ID NO:1] <u>SEQ ID NO:2</u>, and that all three glutamic acids in the positions 17, 21 and 24 of said sequence are gamma-carboxylated.

Serial No. 09/462,931, U.S. National Phase of PCT/FI98/00550, filed 24 June 1998 March 5, 2001 Mark-ups, Page 4

## Amended Abstract: Version with markings to show changes made

#### **ABSTRACT**

The invention relates to an isolated osteocalcin fragment derived from human virus, said fragment being characterized in that at least one of the glutamic acids in the position 17, 21 and 24 of the amino acid sequence (I) is gamma-carboxylated. The invention concerns further a monoclonal antibody or recombinant antibody fragment capable to bind said fragment, a cell lime producing said monoclonal antibody, and an immunoassay for quantitative determination of said fragment. Furthermore, the invention concerns a method for the measurement of the rate of bone turnover (formation and;/or resorption) and/or for the investigation of metabolic bone disorders.